^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    DGKD (Diacylglycerol Kinase Delta)

    i
    Other names: DGKD, Diacylglycerol Kinase Delta, KIAA0145, DGKdelta, Diacylglycerol Kinase, Delta 130kDa, Diglyceride Kinase Delta, DAG Kinase Delta, DGK-Delta, Diacylglycerol Kinase, Delta (130kD), 130 KDa Diacylglycerol Kinase, Diglyceride Kinase, Dgkd-2
    Associations

    News

    Trials
    over1year
    Bioinformatics-Based Identification of Key Prognostic Genes in Neuroblastoma with a Focus on Immune Cell Infiltration and Diagnostic Potential of VGF. (PubMed, Pharmgenomics Pers Med)
    The hub genes (VGF, DGKD, and C19orf52) of neuroblastoma are screened. VGF, one of the hub genes, may have a high diagnostic value and is involved in the immune cell infiltration in neuroblastoma tissue, which may be used as a biomarker for the diagnosis of neuroblastoma and provides a new direction for clinical prognosis prediction and management improvement.
    Journal • Immune cell
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • CD4 (CD4 Molecule) • DGKD (Diacylglycerol Kinase Delta)
    |
    MYCN amplification
    over2years
    Role of Diacylglycerol Kinases in Acute Myeloid Leukemia. (PubMed, Biomedicines)
    These findings underscore the pivotal and isoform-specific involvement of DGKs in AML, offering a promising pathway for the identification of potential therapeutic targets. Notably, the DGKA and DGKH isoforms emerge as relevant players in AML pathogenesis, albeit DGKA inhibition alone seems insufficient to impair AML cell viability.
    Journal
    |
    DGKD (Diacylglycerol Kinase Delta)
    over2years
    Optical Genome Mapping Identifies Novel Recurrent Structural Alterations in Childhood ETV6::RUNX1+ and High Hyperdiploid Acute Lymphoblastic Leukemia. (PubMed, Hemasphere)
    We detected 3 novel fusion genes (SFMBT2::DGKD, PDS5B::STAG2, and TDRD5::LPCAT2), for which the sequence and expression were validated by long-read and whole transcriptome sequencing, respectively. OGM and WES identified double hits of SVs and SNVs (ETV6, BTG1, STAG2, MANBA, TBL1XR1, NSD2) in the same patient demonstrating the power of the combined approach to define the landscape of genomic alterations in BCP-ALL.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RUNX1 (RUNX Family Transcription Factor 1) • ETV6 (ETS Variant Transcription Factor 6) • IKZF1 (IKAROS Family Zinc Finger 1) • PAX5 (Paired Box 5) • STAG2 (Stromal Antigen 2) • CD4 (CD4 Molecule) • DGKD (Diacylglycerol Kinase Delta) • DRD5 (Dopamine Receptor D5) • GPRC5A (G Protein-Coupled Receptor Class C Group 5 Member A) • IKBKB (Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta) • LPCAT2 (Lysophosphatidylcholine Acyltransferase 2) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2) • SFMBT2 (Scm Like With Four Mbt Domains 2) • TBL1XR1 (TBL1X Receptor 1)
    |
    IKZF1 deletion
    almost3years
    Prognostic factors and Doxorubicin involved in malignant progression of meningioma. (PubMed, Sci Rep)
    Moreover, Doxorubicin was identified by Connectivity Map website with the differential malignant progression-related genes. CCK-8 assay, Edu assay, wound healing assay, and trans-well experiment were used to reveal that Doxorubicin could inhibit proliferation, migration and invasion of IOMM-Lee Cells.
    Journal
    |
    MIR664A (MicroRNA 664a) • DGKD (Diacylglycerol Kinase Delta) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2)
    |
    doxorubicin hydrochloride
    almost3years
    Combination Therapy for TKI Resistant Kidney Cancer via Blocking ERβ/circRNA-DGKD/miR-125-5p/VE-cadherin Signal Induced Vasculogenic Mimicry (AUA 2023)
    Our study reveals that the resistance to TKIs (pazopanib or sunitinib) occurs by increasing vasculogenic mimicry (VM) ability to counteract the TKI angiogenesis suppression function. Furthermore, we find a potential therapy to more effectively treat TKI resistant RCC by blocking ERβ/circRNA-DGKD/miR-125-5p/VE-cadherin pathway together with pazopanib administration.
    Combination therapy
    |
    MIR125 (MicroRNA 125) • CDH5 (Cadherin 5) • DGKD (Diacylglycerol Kinase Delta)
    |
    CDH1 expression
    |
    sunitinib • pazopanib
    almost4years
    Identification of a 12-Gene Signature and Hub Genes Involved in Kidney Wilms Tumor via Integrated Bioinformatics Analysis. (PubMed, Front Oncol)
    The model had good predictive power for the WT prognosis at 1, 3, and 5 years (AUC: 0.684, 0.762, and 0.774). Finally, ERRFI1 (hazard ratios [HR] = 1.858, 95% confidence intervals [CI]: 1.298-2.660) and ROR1 (HR = 0.780, 95% CI: 0.609-0.998) were obtained as independent predictors of prognosis in WT patients by single, multifactorial Cox analysis.
    Journal • Gene Signature
    |
    BCL6 (B-cell CLL/lymphoma 6) • ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1) • ERRFI1 (ERBB Receptor Feedback Inhibitor 1) • CCNA1 (Cyclin A1) • DGKD (Diacylglycerol Kinase Delta) • MIR30C